1285513-47-4 Usage
Benzamide derivative
2-(benzyloxy)-5-bromo-N-(pyridazin-3-yl)benzamide is derived from benzamide, which is a basic structure consisting of a benzene ring connected to an amide group (C=O) with an adjacent nitrogen atom.
Benzyl ether
The compound contains a benzyl ether group, which is an aromatic ether group consisting of a benzene ring connected to an ethoxy group (-OCH2-).
Bromine
2-(benzyloxy)-5-bromo-N-(pyridazin-3-yl)benzamide has a bromine atom attached to the 5th position of the benzene ring, which can influence its reactivity, stability, and lipophilicity.
Pyridazine moiety
The compound also contains a pyridazine group, which is a five-membered heterocyclic ring with two nitrogen atoms. This group can contribute to the compound's biological activity and potential pharmaceutical applications.
Potential applications in medicinal chemistry
Due to its diverse structure and potential biological activities, 2-(benzyloxy)-5-bromo-N-(pyridazin-3-yl)benzamide may be useful in the development of pharmaceuticals and other medicinal compounds.
Need for further research
To fully understand the properties and potential uses of 2-(benzyloxy)-5-bromo-N-(pyridazin-3-yl)benzamide, additional research is necessary to explore its biological activities, pharmacokinetics, and safety profile.
Check Digit Verification of cas no
The CAS Registry Mumber 1285513-47-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,8,5,5,1 and 3 respectively; the second part has 2 digits, 4 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1285513-47:
(9*1)+(8*2)+(7*8)+(6*5)+(5*5)+(4*1)+(3*3)+(2*4)+(1*7)=164
164 % 10 = 4
So 1285513-47-4 is a valid CAS Registry Number.
1285513-47-4Relevant academic research and scientific papers
Discovery of 5-substituent-N-arylbenzamide derivatives as potent, selective and orally bioavailable LRRK2 inhibitors
Ding, Xiao,Dai, Xuedong,Long, Kai,Peng, Cheng,Andreotti, Daniele,Bamborough, Paul,Eatherton, Andrew J.,Edge, Colin,Jandu, Karamjit S.,Nichols, Paula L.,Philps, Oliver J.,Stasi, Luigi Piero,Wan, Zehong,Xiang, Jia-Ning,Dong, Kelly,Dossang, Pamela,Ho, Ming-Hsun,Li, Yi,Mensah, Lucy,Guan, Xiaoming,Reith, Alastair D.,Ren, Feng
, p. 4034 - 4038 (2017/08/23)
Leucine-rich repeat kinase 2 (LRRK2) has been suggested as a potential therapeutic target for Parkinson's disease. Herein we report the discovery of 5-substituent-N-arylbenzamide derivatives as novel LRRK2 inhibitors. Extensive SAR study led to the discovery of compounds 8e, which demonstrated potent LRRK2 inhibition activity, high selectivity across the kinome, good brain exposure, and high oral bioavailability.
NOVEL COMPOUNDS
-
, (2011/04/25)
The present invention discloses novel compounds inhibiting LRRK2 kinase activity, the preparation processes thereof, the compositions containing them, as well as the use in treating diseases characterized by LRRK2 kinase activity, particularly Parkinson's disease and Alzheimer's disease.
